Artwork

Content provided by Stephen Jenkins, MD, Austin Rupp, MD, Stephen Jenkins, MD, and Austin Rupp. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Stephen Jenkins, MD, Austin Rupp, MD, Stephen Jenkins, MD, and Austin Rupp or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Semaglutide for CVD in Diabetes, PAD, and MASH, Semaglutide vs Tirzepatide, Normal Saline vs Lactated Ringer's, Oxygen Targets for Intubated Patients, Platelet Transfusion Guidelines, Apixaban vs Rivaroxaban

1:05:06
 
Share
 

Manage episode 489284985 series 3380023
Content provided by Stephen Jenkins, MD, Austin Rupp, MD, Stephen Jenkins, MD, and Austin Rupp. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Stephen Jenkins, MD, Austin Rupp, MD, Stephen Jenkins, MD, and Austin Rupp or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Today we do a round-up of some of the recent semaglutide trials. Does semaglutide ever miss? But what about tirzepatide, which causes even more weight loss?

We also review two new critical care trials, FLUID and the UK-ROX, new platelet transfusion guidelines, and a new retrospective study of apixaban vs rivaroxaban vs warfarin.

Oral Semaglutide for Diabetes with Cardiovascular Disease or CKD (SOUL)

Semaglutide for Peripheral Artery Disease (STRIDE)

Semaglutide for MASH (ESSENCE)

Semaglutide vs Tirzepatide for Obesity (SURMOUNT-5)

Normal Saline vs Lactated Ringers (FLUID)

Conservative Oxygen Targets in Mechanically Ventilated Patients (UK-ROX)

Platelet Transfusion Guidelines

Apixaban vs Rivaroxaban vs Warfarin

Music from Uppbeat (free for Creators!):

https://uppbeat.io/t/soundroll/dope

License code: NP8HLP5WKGKXFW2R

  continue reading

62 episodes

Artwork
iconShare
 
Manage episode 489284985 series 3380023
Content provided by Stephen Jenkins, MD, Austin Rupp, MD, Stephen Jenkins, MD, and Austin Rupp. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Stephen Jenkins, MD, Austin Rupp, MD, Stephen Jenkins, MD, and Austin Rupp or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Today we do a round-up of some of the recent semaglutide trials. Does semaglutide ever miss? But what about tirzepatide, which causes even more weight loss?

We also review two new critical care trials, FLUID and the UK-ROX, new platelet transfusion guidelines, and a new retrospective study of apixaban vs rivaroxaban vs warfarin.

Oral Semaglutide for Diabetes with Cardiovascular Disease or CKD (SOUL)

Semaglutide for Peripheral Artery Disease (STRIDE)

Semaglutide for MASH (ESSENCE)

Semaglutide vs Tirzepatide for Obesity (SURMOUNT-5)

Normal Saline vs Lactated Ringers (FLUID)

Conservative Oxygen Targets in Mechanically Ventilated Patients (UK-ROX)

Platelet Transfusion Guidelines

Apixaban vs Rivaroxaban vs Warfarin

Music from Uppbeat (free for Creators!):

https://uppbeat.io/t/soundroll/dope

License code: NP8HLP5WKGKXFW2R

  continue reading

62 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play